Delivery of AAV1 packaging RfxCas13d, a Cas13 variant targeting hHTT exon 1 in R6/2 HD mice, decreased HTT expression by approximately 50%, suggesting the ability of RfxCas13d to ameliorate HD-linked pathology [124]. Here, HTT is linked to Huntington disease.